Johnston A, Henry J, Warrington S, HAMER N
Br J Clin Pharmacol. 1980; 10(3):245-8.
PMID: 7437241
PMC: 1430074.
DOI: 10.1111/j.1365-2125.1980.tb01751.x.
David B, Madsen B, Ilett K
Br J Clin Pharmacol. 1980; 9(6):614-8.
PMID: 7387819
PMC: 1430006.
DOI: 10.1111/j.1365-2125.1980.tb01090.x.
Landmark K, Bredesen J, Thaulow E, Simonsen S, Amlie J
Eur J Clin Pharmacol. 1981; 19(3):187-92.
PMID: 7215416
DOI: 10.1007/BF00561947.
Maidment C, Hughes R, James I
Br J Clin Pharmacol. 1981; 11(3):310-2.
PMID: 7213534
PMC: 1401630.
DOI: 10.1111/j.1365-2125.1981.tb00542.x.
Giacomini K, Swezey S, Blaschke T
J Pharmacokinet Biopharm. 1982; 10(1):1-14.
PMID: 7069575
DOI: 10.1007/BF01059180.
Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson S, Cairns C, Whiting B
Br J Clin Pharmacol. 1982; 13(3):417-21.
PMID: 7059444
PMC: 1402117.
DOI: 10.1111/j.1365-2125.1982.tb01395.x.
Therapeutic drug monitoring of antiarrhythmic agents.
Brown J, SHAND D
Clin Pharmacokinet. 1982; 7(2):125-48.
PMID: 7039925
DOI: 10.2165/00003088-198207020-00003.
The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.
Wing L, Meffin P, Grygiel J, Smith K, Birkett D
Br J Clin Pharmacol. 1980; 9(5):505-9.
PMID: 6994791
PMC: 1429945.
Pharmacokinetics of disopyramide in patients with chronic renal failure.
Francois B, MALLEIN R, RONDELET J, Lussignol M
Eur J Drug Metab Pharmacokinet. 1983; 8(1):85-92.
PMID: 6861798
DOI: 10.1007/BF03189585.
Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
David B, Ilett K, Whitford E, STENHOUSE N
Br J Clin Pharmacol. 1983; 15(4):435-41.
PMID: 6849779
PMC: 1427808.
DOI: 10.1111/j.1365-2125.1983.tb01527.x.
Clinical pharmacokinetics of disopyramide.
Karim A, Nissen C, AZARNOFF D
J Pharmacokinet Biopharm. 1982; 10(5):465-94.
PMID: 6762414
DOI: 10.1007/BF01059032.
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.
Kumana C, Rambihar V, Willis K, Gupta R, Tanser P, Cairns J
Br J Clin Pharmacol. 1982; 14(4):529-37.
PMID: 6753888
PMC: 1427608.
DOI: 10.1111/j.1365-2125.1982.tb02024.x.
Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Giacomini K, Blaschke T
Clin Pharmacokinet. 1984; 9 Suppl 1:42-8.
PMID: 6705426
DOI: 10.2165/00003088-198400091-00006.
Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.
Postgrad Med J. 1984; 60(700):98-107.
PMID: 6369290
PMC: 2417724.
DOI: 10.1136/pgmj.60.700.98.
Disopyramide pharmacokinetics in patients with acute myocardial infarction.
Pentikainen P, Huikuri H, Jounela A, Wilen G
Eur J Clin Pharmacol. 1985; 28(1):45-51.
PMID: 3987785
DOI: 10.1007/BF00635707.
Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
Elliott H, Thomson A, Bryson S
Eur J Clin Pharmacol. 1986; 30(3):345-7.
PMID: 3732373
DOI: 10.1007/BF00541541.
Clinical pharmacokinetics of disopyramide.
Siddoway L, Woosley R
Clin Pharmacokinet. 1986; 11(3):214-22.
PMID: 3524956
DOI: 10.2165/00003088-198611030-00003.
Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.
Brogden R, Todd P
Drugs. 1987; 34(2):151-87.
PMID: 3304965
DOI: 10.2165/00003495-198734020-00001.
Effects of cardiovascular disease on pharmacokinetics.
Rodighiero V
Cardiovasc Drugs Ther. 1989; 3(5):711-30.
PMID: 2577313
DOI: 10.1007/BF01857622.
Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.
Bauman J, Schoen M, Hoon T
Clin Pharmacokinet. 1991; 20(2):151-66.
PMID: 2029806
DOI: 10.2165/00003088-199120020-00006.
